Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis

References

• Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev. 2017;16(1):10–52.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91–102.
   PubMed Web of Science ®Google Scholar
• Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology. 2019;58(2):336–344.
   PubMed Web of Science ®Google Scholar
• Coates LC, Corp N, van der Windt DA, et al. GRAPPA treatment recommendations: an update from the 2020 GRAPPA annual meeting. J Rheumatol. 2021 Feb 15;Supplement:jrheum.201681. DOI:https://doi.org/10.3899/jrheum.201681
   Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712.
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018 May 17;13(5):e01951.
   Web of Science ®Google Scholar
• Alten R, Conaghan PG, Strand V, et al. Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clin Rheumatol. 2019;38(6):1615–1626.
   PubMed Web of Science ®Google Scholar
• Stober C, Ye W, Guruparan T, et al. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford). 2018;57(1):158–163.
   PubMed Web of Science ®Google Scholar
• Beverly Cheok Kuan NG, Jadon DR. Unmet needs in psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101693.
   PubMed Web of Science ®Google Scholar
• Ariani A, Santilli D, Mozzani F, et al. Cycling or swap biologics and small molecules in psoriatic arthritis. Medicine 2021;100(16):e25300.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus Placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227–1239.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312–320.
   PubMed Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2367–2377.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Deodhar A, Heijde DVD, et al. POS0198 efficany and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled. Ann Rheum Dis. 2021;80(Suppl 1):314–315.
   Google Scholar
• Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–1125.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–1136.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Chohan S, and Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021;80(9) :2020–219014.
   Web of Science ®Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. AB0559 Efficacy and safety of risankizumab in patients with active psoriatic arthritis after inadequate response or intolerance to dmards: 24-week results from the phase 3, randomized, double-blind KEEPsAKE 1 trial. Ann Rheum Dis. 2021;80(Suppl 1):1315–1316.
   Google Scholar
• Ostor A, Bosch FVD, Papp K, et al. OP0228 efficacy and safety of risankizumab for active psoriatic arthritis, including patients with inadequate response or intolerance to biologic therapies: 24-week results from the phase 3, randomized, double-blind, KEEPsAKE 2 TRIAL. Ann Rheum Dis. 2021;80(Suppl 1):138–139.
   Google Scholar
• Oliveira DG, Faria R, Torres T. An overview of bimekizumab for the treatment of psoriatic arthritis: the evidence so far. Drug Des Devel Ther. 2021;15:1045–1053.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–440.
   PubMed Web of Science ®Google Scholar
• Zardin-Moraes M, Silva ALFAD, Saldanha C, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis. J Rheumatol. 2020;47(6):839–846.
   PubMed Web of Science ®Google Scholar